Overall survival (OS) results with Daratumumab (DARA), Lenalidomide and Dexamethasone (D-Rd) Vs Lenalidomide and Dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM): Phase 3 MAIA study

Weisel, K (author)

Facon, T (author)

Kumar, S (author)

show more...

Plesner, T (author)

Orlowski, RZ (author)

Moreau, P (author)

Bahlis, N (author)

Basu, S (author)

Nahi, H (author)

Karolinska Institutet

Hulin, C (author)

Quach, H (author)

Goldschmidt, H (author)

O'Dwyer, M (author)

Perrot, A (author)

Venner, CP (author)

Mace, JR (author)

Raje, N (author)

Tiab, M (author)

Macro, M (author)

Frenzel, L (author)

Leleu, X (author)

Ahmadi, T (author)

Wang, J (author)

Rampelbergh, RV (author)

Uhlar, CM (author)

Tromp, B (author)

Delioukina, M (author)

Vermeulen, J (author)

Usmani, SZ (author)

show less...

 (creator_code:org_t)

2021

2021

English.

In: ONCOLOGY RESEARCH AND TREATMENT. - 2296-5270. ; 44, s. 184-185

Related links:

http://kipublication...

• Conference paper (other academic/artistic)